IDDA Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Innate Pharma SA

Watchlist Manager

Watchlist

Price: 1.58 EUR -1.86% Market Closed

Market Cap: €127.9m

	Innate Pharma SA F:IDDA	FR
R	Red Metal Ltd ASX:RDM	AU
	PacificHealth Laboratories Inc OTC:PHLI	US
U	USA Performance Products Inc OTC:UPRM	US
	Holding Company ADMIE IPTO SA F:08M	GR
V	Vulcan Materials Co DUS:VMC	US
	Vidrala SA OTC:VDRFF	ES
	Regional Management Corp F:46F	US

Profitability Summary

Innate Pharma SA's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Strong 3Y Average Gross Margin

62%

Declining Gross Margin

93% > 1%

Negative Operating Margin

-1.834%

Negative 3Y Average Operating Margin

-653%

Declining Operating Margin

-152% > -1.834%

Negative Net Margin

-1.765%

Negative 3Y Average Net Margin

-615%

Declining Net Margin

-144% > -1.765%

Negative Free Cash Flow Margin

-1.898%

Negative 3Y Average Free Cash Flow Margin

-559%

Declining Free Cash Flow Margin

-74% > -1.898%

Exceptional ROE

764%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-254%

Declining ROIC

-55% > -835%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.